Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia

Mayo Clinic Proceedings
R A MesaA Tefferi

Abstract

To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with myeloid metaplasia (MMM). We analyzed (March 1999 to August 2003) initial and long-term outcomes from 36 patients with symptomatic MMM who had enrolled in either our thalidomide single-agent trial (n=15) or our trial of low-dose thalidomide (50 mg/d) combined with prednisone (n=21). Among the 36 study patients, 20 (56%) showed some improvement in their clinical course. Response rates for specific end points included improvements in anemia (15 of 36 [42%]), thrombocytopenia (10 of 13 [77%]), or splenomegaly (5 of 30 [17%]). The combination of low-dose thalidomide and prednisone, as opposed to single-agent thalidomide, was better tolerated and more efficacious. After a median follow-up of 25 months (range, 20-56 months), 10 of 36 patients (28%) showed an ongoing response, including 8 patients in whom protocol treatment has been discontinued for a median of 21 months (range, 16-31 months). Durable treatment responses were documented for only anemia and thrombocytopenia. Treatment response was not affected by the baseline status of bone marrow fibrosis, angiogenesis, osteosclero...Continue Reading

Citations

Feb 15, 2013·Experimental and Therapeutic Medicine·Lian GuNong Tang
Sep 5, 2006·The Oncologist·Cecilia Arana-YiSrdan Verstovsek
Feb 4, 2006·Current Opinion in Hematology·Ayalew Tefferi
Nov 17, 2006·Expert Opinion on Investigational Drugs·Srdan VerstovsekAyalew Tefferi
Mar 1, 2008·British Journal of Haematology·Gandhi DamajOlivier Hermine
Nov 1, 2011·The Journal of Dermatology·Li LiHongzhong Jin
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayalew Tefferi
Aug 29, 2007·Drugs·Sachin R Shah, Thu M Tran
Nov 27, 2004·Cancer·Bryan T HennessySrdan Verstovsek
Oct 6, 2010·Cancer·Meetu AgrawalAlfonso Quintas-Cardama
Aug 12, 2017·Expert Review of Hematology·Lucia MasarovaNaval Daver
Oct 14, 2005·British Journal of Cancer·J B BartlettJ B Zeldis
Feb 1, 2007·Current Hematologic Malignancy Reports·William J HoganAyalew Tefferi
Feb 14, 2012·Expert Opinion on Pharmacotherapy·Sonia ValletKlaus Podar
May 19, 2009·Expert Review of Anticancer Therapy·Ehab Atallah, Srdan Verstovsek
Oct 1, 2011·Therapeutic Advances in Hematology·Waqas RehmanHillard M Lazarus
Feb 27, 2018·Expert Opinion on Emerging Drugs·Aditya Shreenivas, John Mascarenhas
Aug 12, 2006·American Journal of Clinical Dermatology·Noah Scheinfeld
Mar 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ami B PatelMichael W Deininger
Aug 2, 2006·Archives of Pathology & Laboratory Medicine·Lawrence Rice, Kelty R Baker
Oct 8, 2005·Seminars in Hematology·Giovanni Barosi, Ronald Hoffman
Nov 16, 2021·Leukemia & Lymphoma·Prithviraj Bose, Ruben A Mesa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.